Pancreatic Beta Cells Synthesize Neuropeptide Y and Can Rapidly Release Peptide Co-Transmitters by Whim, Matthew D.
Pancreatic Beta Cells Synthesize Neuropeptide Y and Can
Rapidly Release Peptide Co-Transmitters
Matthew D. Whim*
Department of Cell Biology and Anatomy, Louisiana State University (LSU) Health Sciences Center, New Orleans, Louisiana, United States of America
Abstract
Background: In addition to polypeptide hormones, pancreatic endocrine cells synthesize a variety of bioactive molecules
including classical transmitters and neuropeptides. While these co-transmitters are thought to play a role in regulating
hormone release little is known about how their secretion is regulated. Here I investigate the synthesis and release of
neuropeptide Y from pancreatic beta cells.
Methodology/Principal Findings: NPY appears to be an authentic co-transmitter in neonatal, but not adult, beta cells
because (1) early in mouse post-natal development, many beta cells are NPY-immunoreactive whereas no staining is
observed in beta cells from NPY knockout mice; (2) GFP-expressing islet cells from an NPY(GFP) transgenic mouse are
insulin-ir; (3) single cell RT-PCR experiments confirm that the NPY(GFP) cells contain insulin mRNA, a marker of beta cells.
The NPY-immunoreactivity previously reported in alpha and delta cells is therefore likely to be due to the presence of NPY-
related peptides. INS-1 cells, a beta cell line, are also NPY-ir and contain NPY mRNA. Using the FMRFamide tagging
technique, NPY secretion was monitored from INS-1 beta cells with high temporal resolution. Peptide release was evoked by
brief depolarizations and was potentiated by activators of adenylate cyclase and protein kinase A. Following a transient
depolarization, NPY-containing dense core granules fused with the cell membrane and discharged their contents within a
few milliseconds.
Conclusions: These results indicate that after birth, NPY expression in pancreatic islets is restricted to neonatal beta cells.
The presence of NPY suggests that peptide co-transmitters could mediate rapid paracrine or autocrine signaling within the
endocrine pancreas. The FMRFamide tagging technique may be useful in studying the release of other putative islet co-
transmitters in real time.
Citation: Whim MD (2011) Pancreatic Beta Cells Synthesize Neuropeptide Y and Can Rapidly Release Peptide Co-Transmitters. PLoS ONE 6(4): e19478.
doi:10.1371/journal.pone.0019478
Editor: Kathrin Maedler, University of Bremen, Germany
Received July 21, 2010; Accepted April 7, 2011; Published April 29, 2011
Copyright:  2011 Matthew D. Whim. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the National Institutes of Health to MDW (DK080441). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The author has declared that no competing interests exist.
* E-mail: mwhim@lsuhsc.edu
Introduction
Located within the islets of Langerhans, pancreatic beta cells
synthesize the hormone insulin. A rise in the level of blood glucose
triggers beta cell activity and an increase in insulin secretion.
Consequently glucose uptake by insulin-sensitive cells is acceler-
ated and the circulating levels of glucose are homeostatically
adjusted. However in addition to insulin, beta cells also synthesize
a range of other bioactive molecules. These include small molecule
classical transmitters such as ATP and GABA and larger molecules
including peptides [1,2,3,4]. It is thought that such transmitters
play a role in modulating the activity of islet cells, including beta
cells [5]. For example GABA is secreted from beta cells and
activation of islet GABAB receptors can regulate the secretion of
insulin [6]. However while the existence of beta cell co-
transmitters has been recognized for some time, the factors that
govern their release are not entirely clear.
Neuropeptide Y (NPY) is an example of a pancreatic co-
transmitter that seems to have a modulatory role. NPY is found in
pancreatic islets [7,8] and its exogenous application suppresses
insulin release from perfused islets [9]. In NPY knockout mice the
circulating levels of insulin become abnormally elevated when the
animals are fed ad lib [10]. Finally, deletion of the NPY1 receptor
leads to an increase in plasma insulin levels [11]. These results are
consistent with the prevailing idea that NPY is an autocrine or
paracrine inhibitory co-transmitter within the pancreas.
However a number of issues remain unclear. First, which islet
cells contain NPY? Some studies have concluded that NPY is
primarily expressed in beta cells [4,12,13] while others have
reported that it is found in the glucagon secreting alpha cells [14] or
in the somatostatin-containing delta cells [15]. Because the NPY-
relatedpeptides,pancreaticpolypeptideandPYYarealsopresentin
islets it has been suggested that some of the reported NPY-ir could
be due to the presence of these other peptides [4]. NPY-ir is also
found in neuronal processes within the pancreas [16]. Second, how
is the release of these co-transmitters regulated? Peptides like NPY
and proteins like insulin are synthesized via the endoplasmic
reticulum and packaged into dense core granules as they move
through the trans-Golgi. Previous studies have shown that when
insulin-containing dense core granules fuse with the cell membrane,
the release of insulin can be delayed for hundreds of milliseconds,
which may be related to a slow dissolution of the insulin-containing
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are released unhindered [18]. Whether the secretion of neuropep-
tides like NPY show a delayed release is not known.
To address these questions I have used a variety of approaches
to confirm that NPY expression is confined to mouse beta cells
during early post-natal development. By examining the distribu-
tion of NPY immunoreactive cells in wild type, NPY knockout and
NPY(GFP) animals I conclude that this peptide is not expressed in
alpha, delta or F cells. Because the INS-1 beta cell line also
synthesizes NPY, the kinetics of NPY release was then monitored
from these cells using the FMRFamide tagging technique. The
advantage of this electrophysiological approach is that it can
measure secretion with millisecond resolution. I find that most
peptidergic secretory events are brief suggesting that peptides like
NPY can be rapidly liberated from fusing dense core granules.
Application of the FMRFamide tagging technique may be useful
in future studies examining the release of similar co-transmitters
from other pancreatic endocrine cells.
Results
Neuropeptide Y is expressed in mouse pancreatic beta
cells
When dissociated cultures of pancreatic cells from neonatal
mice (P0–P2) were co-stained for NPY and insulin, a population of
cells was identified that contained punctate NPY-immunoreactiv-
ity (NPY-ir) as expected for a transmitter located in the regulated
secretory pathway (Figure 1A). Most insulin-ir cells were also
NPY-ir (70%; 19/27 cells). To determine if NPY and insulin were
present in the same granules, the red and green fluorescent signals
from single puncta were quantified. Many puncta were co-labeled
(Figure 1B) and there was a positive correlation (R=0.86) in the
intensity of the NPY- and insulin-ir (Figure 1C, left panel). A
histogram of the intensity ratios also had a dominant peak
suggesting that the majority of NPY-containing granules contained
insulin (Figure 1C, right panel).
As seen in Figure 1A, some of the NPY-ir cells were not insulin-
ir and therefore to determine which islet cells expressed NPY the
cultures were co-stained for insulin, glucagon and somatostatin
(possible co-existence of pancreatic polypeptide and NPY was
tested using a transgenic approach; see below). In neonatal animals
NPY-ir was co-localized with insulin-, glucagon- and somatostatin-
immunoreactivity (not shown). When islet cells from adult mice
(P25) were examined, a somewhat different picture emerged. In
these animals NPY-ir was still found in glucagon- and somato-
statin-ir cells, but not in insulin-ir cells (not shown). These results
suggested that (1). NPY expression was developmentally regulated
or (2). the NPY antibody was also recognizing the related peptides,
PYY and PP, which are known to be present in pancreatic islets
[4]. To test the latter possibility, NPY-ir was examined in neonatal
islet cells isolated from an NPY knockout mouse. In these cultures,
although no NPY-ir was observed in insulin-ir cells, ‘‘NPY-ir’’ was
still present in glucagon- and somatostatin-ir cells (Figure 1D).
Thus in neonates NPY appears to be present in beta cells but the
‘‘NPY-ir’’ in alpha and delta cells is likely to be PYY or PP.
Given these complications two additional approaches were used
to confirm the distribution of NPY expression. First, pancreatic
cells were isolated from a BAC transgenic mouse in which GFP is
expressed in cells that synthesize NPY [19]. In cultures from
neonatal animals, GFP expression was found only in insulin-ir cells
but was absent from glucagon-, somatostatin- and PP-ir cells
(Figure 2A). A similar result was observed in islet cells from adult
animals (Figure 2B). These results are in agreement with the data
from the NPY knockout animals and indicate that in neonates
NPY expression is limited to beta cells. However in adult islets a
discrepancy exists; GFP expression is seen in insulin-ir cells but
NPY-ir was absent from insulin-ir cells. To reconcile these
observations I considered the possibility that it might be due to
Figure 1. Neuropeptide Y is synthesized by mouse pancreatic
beta cells. (A). A small cluster of pancreatic cells in which some insulin-
ir (beta) cells are also NPY-ir (arrow indicates one example). Also present
is a beta cell that is not NPY-ir (arrow head). (B). Single confocal slice
through an insulin-ir cell that was also NPY-ir. Indicated are two puncta
that are co-stained for NPY and insulin (arrows). (C). Quantification of
the fluorescent signal from individual puncta. ROI’s corresponding to
single NPY-ir puncta were selected then the corresponding signal in the
insulin (red) channel was also measured. Left panel; a plot of
fluorescence intensities indicates that there is a positive correlation
between the signal in the two channels consistent with the
coexpression of NPY and insulin in individual granules (n=90 granules
from 3 cells, R=0.86). Right panel; the distribution of the punctal
signals. (D). Islet cells from a neonatal (P0) NPY knockout animal were
co-stained for NPY, insulin, glucagon and somatostatin. NPY-ir was not
present in insulin-ir cells (arrow head), while punctate ‘‘NPY-ir’’ was seen
in both glucagon- and somatostatin-ir cells (arrows). Thus authentic
NPY-ir is only present in beta cells. Scale bars 10 mm (A,D) 5 mm (B).
doi:10.1371/journal.pone.0019478.g001
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secretory granules. If NPY synthesis were to cease during early
post-natal development it is possible that cytoplasmic GFP would
persist but that no NPY-ir would be observed.
To test this idea neonatal and adult islet cells from the BAC
NPY(GFP) mice were stained for NPY. If a developmental switch
occurred the prediction was that neonatal GFP cells would stain
for NPY, but that adult GFP cells would not. This was indeed the
case. As shown (Figure 2C) neonatal GFP cells were NPY-ir
(n=14 cells). However in adults none of the GFP-expressing cells
were NPY-ir (n=24 cells) although ‘‘NPY-ir’’ islet cells were
present (Figure 2D). The latter are likely to be the putative PYY-
or PP-expressing cells described above.
Thus after birth, the expression of NPY appears to be restricted to
neonatal beta cells. As noted previously [4] a marked reduction in
NPY expression occurred during the first postnatal week (only 12%
(3/26) insulin-ir cells were NPY-ir at P5; not shown). Co-localization
of GFP expression and insulin-ir was also seen in thin sections of
pancreatic tissue from neonatal animals (Figure 2E) indicating that
NPY-ir is expressed by beta cells in situ as well as in vitro.
Finally, if the neonatal NPY(GFP) expressing cells were indeed
beta cells they should contain insulin mRNA. Single cell RT-PCR
experiments confirmed that this was the case in all 8 cells
examined (Figure 2F). Thus multiple lines of evidence are
consistent with the idea that NPY is present in a population of
beta cells early in post-natal development.
Figure 2. NPY is expressed in neonatal, but not adult, beta cells. (A). GFP expressing pancreatic cells from a neonatal (P0) NPY(GFP)
transgenic mouse were stained for insulin, glucagon, somatostatin and pancreatic polypeptide. GFP was present only in cells that were insulin-ir
(arrow; top panel). Also shown is a beta cell that does not express GFP (arrow head). (B). The same co-localization of GFP and insulin-ir (arrow; top
panel) was seen in pancreatic cells from an adult (P25) NPY(GFP) transgenic animal. GFP was not expressed in glucagon-, somatostatin- or pancreatic
polypeptide-ir cells. (C). GFP expressing cells from a neonatal (P0) NPY(GFP) animal are also NPY-ir. (D). Conversely none of the GFP cells from an adult
(P39) NPY(GFP) animal were NPY-ir (top panel) even though NPY-ir cells were present in the culture (lower panel). (E). Thin section of a pancreatic islet
from a P0 NPY(GFP) mouse showing that many GFP expressing cells are also insulin-ir (arrow indicates one example). Scale bars 10 mm (A–D); 50 mm
(E). (F). Single cell RT-PCR showing that GFP expressing cells from a neonatal (P0) NPY(GFP) animal also contain insulin mRNA. Shown are 4 cells, and
two controls (‘‘Water’’ and ‘‘RT neg’’ which lacked either cellular material or reverse transcriptase, respectively). A single amplicon is present at the
expected size for insulin (241 bp).
doi:10.1371/journal.pone.0019478.g002
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pancreatic beta cell line
To examine the secretion of neuropeptide Y the INS-1 beta cell
line was used. When INS-1 832/13 cells were stained with an NPY
antibody, punctate NPY-ir was observed in the cell body and in the
tips of the processes. All INS-1 cells were insulin-ir and the majority
of the NPY-ir puncta were co-localized with the insulin-ir puncta
(Figure 3A). Quantification of the fluorescent signal in the red and
green channels indicated that individual puncta contained both
NPY- and insulin-ir and that there was a positive correlation in the
relative intensities of the two signals (Figure 2B, left panel) consistent
with the co-expression of NPY and insulin in single granules. A
histogram of the intensity ratios had a single peak (Figure 3B, right
panel). These results are in agreement with the co-localization of
NPY and insulin seen in primary beta cells (Figure 1B,C).
Next INS-1 cells were transfected with a plasmid encoding the NPY
prohormone in which venus was fused to the carboxyl terminus of
NPY. In transfected cells fluorescent puncta were seen in the cell body
and at the tips of the processes (Figure 3C). Thus INS-1 cells contain
the synthetic pathways needed for processing of the NPY prohormone.
Finally RT-PCR experiments confirmed that INS-1 832/13
cells contained both rat insulin and NPY mRNA. As expected they
also expressed the MafA gene which encodes a transcription factor
characteristic of beta cells (Figure 3D). These results are consistent
with previous studies [20,21] and the idea that INS-1 cells, like
beta cells, synthesize NPY.
Neuropeptide Y release monitored from INS-1 beta cells
with the FMRFamide tagging technique
To determine whether NPY is secreted from beta cells in an
activity-dependent manner the FMRFamide tagging technique
was used [22]. In this approach the cells are transfected with
several plasmids. One encodes the NPY prohormone which has
been tagged with the coding sequence for the peptide FMRFa-
mide. Expression of the tagged prohormone results in the synthesis
of NPY and FMRFamide. Since these peptides are present on the
same prohormone they are subsequently co-packaged into the
same dense core granules. The cells are also transfected with a
plasmid encoding the ionotropic FMRFamide receptor (and GFP
to identify the transfected cells). When secretion is evoked by a
voltage clamp depolarization the released FMRFamide activates
the FMRFamide receptors on the same cell leading to an inward
autaptic secretory current. The release of FMRFamide is thus used
as a marker for the co-secretion of NPY. The advantage of this
method is that it can follow peptide secretion on a rapid timescale
and can detect release from single granules [22,23].
To confirm that INS-1 cells can synthesize FMRFamide, cells
were transfected with the FMRFamide-tagged NPY prohormone
and GFP. FMRFamide-ir was observed in co-transfected cells but
not in cells expressing only GFP (Figure 4A,B). Thus INS-1 cells
do not contain an endogenous FMRFamide-like peptide.
When transfected cells were stimulated with a train of depolarizing
steps, rapid inward currents were observed (Figure 4C). Removal of
extracellular calcium prevented the appearance of the events
(Figure 4D), consistent with the idea that they are due to calcium-
dependent transmitter release. Four types of experiments indicated that
these events were due to secretion of the FMRFamide tag. First, no
events were detected from cells that were transfected with a tagged
NPY prohormone in which FMRFamide was irreversibly fused to the
C-terminusofNPYbyremovingthedibasiccleavagesignal(Figure4E).
The absence of secretory events is expected because the ionotropic
FMRFamide receptor is not activated by extended peptides like NPY-
FMRFamide [24]. Second, the events required expression of the
ionotropic FMRFamide receptor because they were not observed
when cells were transfected only with the FMRFamide tagged NPY
prohormone. However events were seen in sister cultures transfected
with the tagged prohormone and the receptor (Figure 4F). Third,
exogenous application of FMRFamide evoked an inward current only
in cells that were transfected with the FMRFamide receptor, but not in
untransfected cells (Figure 4G). Fourth, the amplitude of the secretory
events was reduced in the presence of 100 mM amiloride (Figure 3H;
298687 pA vs. 16623 pA; mean 6 SD; n=5 cells; P=0.067), a
drug that inhibits the iontropic FMRFamide receptor [25]. These
experiments indicate that generation of the secretory currents requires
the release of FMRFamide, and that INS-1 cells do not endogenously
express a FMRFamide-activated receptor.
Figure 3. The INS-1 832/13 beta cell line synthesizes neuro-
peptide Y. (A). INS-1 cells were examined for both insulin- and NPY-ir.
The merged image shows that the insulin- and NPY-ir co-localizes in
individual cells (arrow). Scale bar 20 mm. (B). Quantification of the
fluorescent signal from immunoreactive puncta. Left panel; a plot of
fluorescence intensities indicates a positive correlation between the
level of NPY- and insulin-ir consistent with the coexpression of NPY and
insulin in individual granules (n=30 granules from 6 cells, R=0.62).
Right panel; the distribution of the punctal signals. (C). INS-1 cells were
transfected with a venus tagged NPY prohormone then stained for
insulin-ir. Punctate NPY-venus fluorescence indicates that INS-1 cells
have the ability to process the NPY prohormone. Scale bar 20 mm.
(D). RT-PCR experiment showing the generation of amplicons
consistent with the presence of MafA, insulin and NPY mRNA in INS-1
cells. All primers were intron spanning.
doi:10.1371/journal.pone.0019478.g003
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19478Figure 4. Neuropeptide Y release monitored from INS-1 beta cells with the FMRFamide tagging technique. (A). INS-1 cells that were
transfected with GFP did not show any FMRFamide-ir. (B). INS-1 cells co-transfected with both GFP and the FMRFamide tagged prohormone were
FMRFamide-ir. Scale bar 20 mm. (C). Example of secretory currents recorded from a cell that was transfected with the ionotropic FMRFamide receptor
and the FMRFamide tagged NPY prohormone. Secretion was evoked with a train of 100 depolarizations at 5 Hz. Each depolarizing step lasted 20 ms
and was from 280 to +20 mV. Sample traces (below; first 10 depolarizations) show that secretion was first detected following the fifth depolarization
(red trace). (D). Secretory currents were not evoked from transfected cells when calcium was removed from the extracellular solution (and 2 mM
EGTA was added). Secretion was evoked as in (C) except that the depolarization lasted 25 ms and was from 260 to +20 mV (n=5 cells, mean 6 SD).
Sample recordings are shown above. (E). Secretory currents were consistently evoked from cells that were transfected with the FMRFamide receptor
and a FMRFamide tagged NPY prohormone (‘‘NPY.Fa’’). In contrast no secretory events were observed in cells transfected with the FMRFamide
receptor and a tagged prohormone in which the cleavage of FMRFamide was prevented (‘‘NPY-Fa’’). Cells were stimulated with the protocol
described in (C). Sample recordings are shown above (n=11–12 cells; mean 6 SD). (F). Secretory events were evoked from cells co-transfected with
NPY.Fa and the FMRFamide receptor (‘‘+FaNaCh’’) but were not evoked from cells transfected only with NPY.Fa (‘‘2FaNaCh’’). Cells were stimulated as
in (C). Sample recordings are shown above (n=6–9 cells, mean 6 SD). (G). Application of exogenous 400 nM FMRFamide evoked an inward current
only in cells that were transfected with both GFP and the ionotropic FMRFamide receptor (n=4–5 cells; mean 6 SD). Thus the secretory currents
require the release of FMRFamide and INS-1 cells do not express an endogenous ionotropic FMRFamide receptor. (H). The mean amplitude of the
secretory currents was lower in cells stimulated in the presence of 100 mM amiloride, a drug that inhibits the ionotropic FMRFamide receptor. Cells
were stimulated with a train of 50 depolarizations using the protocol described in (D). Sample recordings are shown above (n=5 cells, mean 6 SD;
n=5 cells; P=0.067, Mann-Whitney test).
doi:10.1371/journal.pone.0019478.g004
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rapid kinetics from INS-1 beta cells
When transfected INS-1 cells were stimulated with a train of
20 ms depolarizations at 5 Hz, secretory events began after a
delay. A plot of the cumulative amplitude of the secretory events
vs. time was linear indicating that once a threshold was reached,
secretion occurred at a constant rate (Figure 5A). The secretory
events were also not tightly coupled to the depolarizing step
(Figure 5B) and the release probability did not vary substantially
during a train of 100 depolarizations (Figure 5C). The lack of tight
temporal coupling was seen both in whole cell (Figure 5B) and
perforated patch configuration (Figure 5D). Thus it is unlikely to
be due to dialysis of the cell interior. In fact these features are
characteristic of peptide secretion and have been seen in a number
of (neuro)endocrine cell types [26,27].
The amplitude of the peptidergic secretory currents showed a
wide variability (Figure 5E; 124639 pA; mean 6 SD, n=4 cells).
Most events had a rise time of a few milliseconds (Figure 5F,
1.460.5 ms; mean time to rise to half-amplitude 6 SD, n=4
cells). This value sets an upper estimate on the time course of the
escape of the peptide tag from a fusing secretory granule. The
secretory currents also decayed rapidly (Figure 5G, 8.761.9 ms,
mean decay time constant 6 SD, n=4 cells). Although peptide
release was most effectively triggered by a train of depolarizations,
release did not facilitate. Thus when the amplitude of the first and
last events in a train of 100 depolarizations were compared there
was actually a trend towards a decrease although this was not
statistically significant (Figure 5H).
Insulin release from beta cells is potentiated by an increase in
the intracellular levels of cAMP [28,29]. The FMRFamide tagging
technique was then used to determine whether peptide release was
similarly modulated. Application of 5 mM forskolin led to an
increase in the number of peptidergic secretory events (Figure 6A).
As seen in the example experiment shown in Figure 6B, forskolin
resulted in a marked and sustained increase in peptide secretion
monitored as the cumulative amplitude of the secretory events vs.
time. The effect of forskolin was subsequently quantified by
comparing the rate of secretion before and after forskolin addition.
The group data revealed that forskolin led to a significant increase
in peptide secretion (Figure 6C). In beta cells a rise in intracellular
cAMP elevates insulin release via both PKA and EPAC-dependent
pathways [30]. To test whether these pathways can regulate NPY/
FMRFamide release, cAMP analogues that selectively activate
either PKA or EPAC were included in the patch pipette solution.
Depolarizing trains were applied 2 mins after break-in and evoked
peptidergic events were quantified from interleaved control and
experimental cells. Intracellular application of 100 mMN
6-
benzoyl-cAMP, a selective activator of PKA [31], was associated
with a significant increase in peptide secretion (Figure 6D).
Conversely 100 mM2 9-O-Me-cAMP, an EPAC activator [32],
2006), did not increase secretion, although a trend towards
elevated release was observed (Figure 6E). These results suggest
that activation of PKA is able to potentiate the release of both
insulin and peptide co-transmitters from pancreatic beta cells.
Discussion
Here I show that neonatal pancreatic beta cells synthesize
neuropeptide Y as a co-transmitter in addition to the hormone
insulin. This conclusion is based upon three observations. First,
NPY-ir cells are also insulin-ir, the synthesis of the latter hormone
being a characteristic marker of beta cells. No NPY-ir is seen in
beta cells from NPY knockout mice confirming the immunoreac-
tive signal is due to authentic NPY. Second, pancreatic GFP-
expressing cells from a NPY(GFP) transgenic mouse are insulin-ir
but do not stain with markers of alpha, delta or F cells. Third,
using single cell RT-PCR, the GFP-expressing cells were shown to
contain insulin mRNA. Although it has been reported that NPY is
present in alpha- and somatostatin-containing cells, the present
results are in agreement with other studies that localized NPY to
Figure 5. Release of a peptide co-transmitter from INS-1 beta
cells occurs with rapid kinetics. (A). Plot of the cumulative
amplitude of the secretory events vs. time from INS-1 cells that were
stimulated with a train of 100 depolarizations (same protocol as
Figure 4C). After a threshold is passed (grey bar; ,5 depolarizations at
this frequency), secretion occurs at a constant rate as indicated by the
linear fit of the data (n=6 cells, mean 6 SD, R=0.99). (B). Plot of the
occurrence of individual secretory events. Although some events
appear soon after the depolarizing step (grey bar) many events are
not tightly locked to the depolarizing step (n=6 cells). (C). Release
probability did not vary substantially during a train of 100 depolariza-
tions (stimulation protocol as in Figure 4C). Values are presented in 5
sweep bins (n=6 cells; mean 6 SD). (D). A lack of tight temporal
coupling was also seen in the perforated patch configuration (n=4 cells
stimulated with 22 depolarizations from 280 to +20 mV at 1 Hz).
(E–G). Plot of the amplitude, rise time and decay time constants of the
secretory events recorded in the perforated patch configuration (n=4
cells). (H). The amplitude of the first and last secretory events triggered
by a train of 100 depolarizations at 5 Hz (n=6 cells; mean 6 SD; NS;
P=0.08, paired two-tailed t test).
doi:10.1371/journal.pone.0019478.g005
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early post-natal development. By P25 there appears to a
substantial down-regulation of NPY expression as noted by others
[4]. In fact NPY expression appears to be characteristic of an early
stage of beta cell development. For example the loss of the neuroD
transcription factor in insulin-synthesizing cells results in immature
beta cells and elevated islet NPY [13]. Nevertheless the postnatal
loss of NPY does not seem to be irreversible because dexameth-
asone treatment can elevate islet NPY expression in adult rodents
[33].
The idea that pancreatic endocrine cells can express co-
transmitters in addition to their major polypeptide hormones is
now widely accepted. Nevertheless the physiological role of these
secreted co-transmitters is unclear and a subject of active
investigation. However such co-transmitters are likely to be
involved in modulating the secretion of pancreatic hormones by
an autocrine or paracrine mode of action [34]. For example,
GABA and ATP are synthesized by beta cells in addition the
hormone insulin. Both molecules can regulate insulin secretion
from beta cells [5,6]. Likewise the classical transmitter glutamate is
synthesized and secreted by alpha cells in addition to the hormone
glucagon. Release of glutamate from these cells can increase
glucagon release via autocrine feedback [35]. Alpha cells are also
thought to express PYY [4]. Whether the other pancreatic
endocrine cells, which include the somatostatin synthesizing delta
cells, the pancreatic polypeptide synthesizing F cells and the
ghrelin synthesizing epsilon cells also contain co-transmitters is less
clear.
Using FMRFamide tagging the secretion of NPY was
monitored from INS-1 beta cells. Previously the secretion of
neuropeptides from the endocrine pancreas has been followed
using methods which have low temporal resolution such as by RIA
or the use of GFP-tagged fusion proteins. The non-specific NPY-ir
that was seen in alpha, delta and F cells emphasizes the difficulties
Figure 6. Release of a peptide co-transmitter from INS-1 beta cells is potentiated by cAMP. (A). Example of secretory events recorded
from a transfected INS-1 cell before and after the application of 5 mM forskolin. The number of secretory events are indicated by the filled symbols to
the right of the records. Shown are sections of 5 consecutive traces before (sweeps 1–5) and 5 consecutive traces after (sweeps 58–62) the application
of forskolin. (B). Example experiment showing the time course of the potentiating effect of 5 mM forskolin on peptide secretion (open circles; same
cell as in A). Square symbols show the amplitude of the depolarization-evoked calcium current over the course of the experiment. (C). Group data
showing the effect of forskolin (n=8 cells). The effect was quantified by comparing the gradient of the time-cumulative event amplitude relationship
before and after the addition of 1–5 mM forskolin (n=8 cells; mean 6 SD; P,0.05, paired one-tailed t test). Cells in (A–C) were stimulated using the
perforated patch technique at 0.1 or 1 Hz with a 20 ms depolarizing step from 280 to +20 mV. (D). Inclusion of 100 mMN
6-benzoyl-cAMP, a selective
activator of PKA, in the whole cell patch pipette solution significantly potentiated peptide secretion (n=8 cells, mean 6 SD; P,0.05, Mann-Whitney
test). (E). Inclusion of 100 mM2 9-O-Me-cAMP, an EPAC activator, in the pipette solution did not significantly increase peptide secretion (n=6 cells,
mean 6 SD; P,0.05, Mann-Whitney test). Cells in D and E were stimulated as described (Figure 4C).
doi:10.1371/journal.pone.0019478.g006
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with techniques (such as RIA’s) that rely on the use of antibodies.
Using the FMRFamide tagging technique peptide secretion was
found to occur via the regulated secretory pathway because it was
calcium-dependent and required a depolarizing train. Previous
studies using dexamethasone-treated RINm5F beta cells showed
that NPY release was calcium-independent and not altered by
potassium-induced depolarization [36]. Why peptide release
differs between the two cell types is not clear. One possibility is
that the constitutive release of peptide reflected a limitation in the
number of dense core granules, with the ‘‘excess’’ peptide being
diverted to the constitutive pathway [37].
Using FMRFamide tagging the majority of the peptidergic
secretory events had a rise time of a few milliseconds which is
comparable to the kinetics of peptidergic events observed in
neuroendocrine chromaffin cells using the same approach [23].
This is curious because the primary transmitter(s) in chromaffin
cells are the small molecules epinephrine and norepinephrine,
while insulin plays this role in beta cells. The latter has a complex
quaternary structure and is present in a crystalline form within the
secretory granule. These features have consequences for hormone
release. For example insulin is probably too large to exit through
the initial fusion pore and even after full fusion the dissolution of
the insulin core is thought to limit the release of the hormone [17].
In fact although the initial fusion pore is likely to delay the release
of insulin, the escape of the small molecule co-transmitter ATP
appears unhindered [18]. The rapid rise and decay times of the
peptidergic secretory currents measured in this study imply that
the escape of the FMRFamide peptide tag is not delayed. Thus
small peptides like FMRFamide and perhaps NPY (molecular
weight 599 and 4272, respectively) appear more similar in their
release kinetics to classical transmitters than to hormones like
insulin (molecular weight 5808). While it is possible that
FMRFamide and NPY are present in granules that lack insulin,
in both primary beta cells and in the INS-1 cell line, many insulin-
and NPY-ir puncta were co-localized. Thus it seems likely that
these transmitters are co-packaged in at least a subset of the dense
core granules.
Peptide release from transfected INS-1 cells was elevated by
forskolin and N
6-benzoyl-cAMP, an activator of PKA. Previous
work has shown that forskolin also increases the release of
endogenous NPY from INS-1 cells [20]. While insulin secretion
from beta cells is potentiated by cAMP via PKA-dependent and
independent (EPAC) pathways, an EPAC activator did not
significantly alter NPY/FMRFamide release. Whether this reflects
a difference in the mechanisms that regulate peptide and insulin
release is not clear. Overall there appear to be many similarities.
Although the role of the released NPY was not investigated in
the present study, previous work has shown that exogenous NPY
can inhibit insulin release [9] via the activation of NPY1 receptors
[38]. If Y1 receptors are present on beta cells [39] this might
represent a short feedback loop that could act to suppress an
excessive or pathological release of insulin. One complication is
that NPY-ir was not detectable in the adult pancreas. Thus under
normal circumstances the endogenous agonist for these receptors
is probably PYY. However a post-natal role for NPY could exist
under pathological conditions. For example when glucocorticoid
levels are elevated or during type II diabetes, the pancreatic levels
of NPY are reported to increase [33,40,41].
If under physiological conditions NPY is mainly expressed in
immature islets it is unlikely to play a significant role in regulating
blood glucose levels since maturation of the pancreatic response to
glucose is thought to take place after birth [42,43]. What might be
the function of pancreatic NPY if it is not usually present in the
post-natal mouse? Since the global knockout of NPY is associated
with an increase in islet size [10], in future work it might be
informative to examine whether NPY is involved in regulating
early pancreatic development.
Materials and Methods
Ethics statement
All procedures involving animal tissue were approved by the
Institutional Animal Care and Use Committee of LSU Health
Sciences Center, New Orleans (#2711).
Cell preparations
INS-1 832/13 cells (kindly provided by Dr.’s Christopher
Newgard (Duke University), Douglas Cavener (PSU) and Kim
Pedersen (LSUHSC)) were maintained in RPMI/10% FCS
containing 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate
and 1 mM HEPES. Cells were plated on poly-d-lysine coated
coverslips (immunocytochemistry) or on uncoated 35 mm culture
dishes (electrophysiology). Islet cells (P0–39) were isolated either
from wild type C57BL/6J mice, a BAC transgenic line (Npy-
hrGFP) in which cytoplasmic GFP is expressed in cells that
synthesize NPY [19] or NPY knockout animals [44]. All lines
were obtained from The Jackson Laboratory. Briefly, the
pancreas was removed, cut into small pieces and incubated for
20–30 minutes in collagenase type XI at 37uC. The tissue was
washed, re-suspended in 1 ml Histopaque-1077 and triturated.
Culture medium (0.2 ml) was overlaid and the sample was
centrifuged at 900 g for 12 minutes. Tissue in the supernatant (or
handpicked islets in the case of adult animals) was collected and
incubated in HEPES-buffered salt solution containing 1 mM
EDTA for 5 minutes and then gently triturated to release single
cells. The dispersed cells were plated on in the same culture
medium as INS-1 cells.
Electrophysiology
Whole cell and perforated patch clamp recordings were made
with a Multiclamp 700A amplifier (Molecular Devices) as
described [22,23]. Cells were superfused with an extracellular
solution containing (in mM) 135 NaCl, 3 KCl, 2 CaCl2, 1 MgCl2,
10 HEPES, and 5 glucose, pH 7.3, with NaOH. The pipette
solution contained (in mM) 120 K-acetate, 15 KCl, 5 NaCl, 10
HEPES, 4 MgATP and 0.3 NaGTP, pH 7.2 with KOH. In
experiments in which the calcium current was monitored the
pipette solution contained (in mM) 120 Cs-acetate, 15 CsCl, 5
NaCl, 10 HEPES, 4 MgATP, 0.3 NaGTP, pH 7.2 with CsOH.
Some recordings (Figure 5D–G; 6A–C) were made using the
perforated patch technique in which the pipette solution contained
0.1 mg/ml amphotericin B (and lacked ATP and GTP). All
experiments except Figure 4G were conducted at ,33uC. Most
chemicals were obtained from Sigma-Aldrich except for N
6-
benzoyl-cAMP and 29-O-Me-cAMP (Biolog).
Pipette resistance was generally ,6M V and no compensation
was applied. Access resistance was typically 15–25 MV. Secretory
currents were analyzed using pClamp9 (Molecular Devices),
OriginPro7 (Microcal Software, Northampton, MA) and Excel
(Microsoft, Seattle, WA). Statistical significance was assessed using
the Students t test or Mann-Whitney test as indicated.
FMRFamide tagging was as previously described [22]. Cells
were transfected with 0.2 mg pGFP/0.65 mg pFaNaCh/0.65 mg
pNPY.Fa using Lipofectamine 2000 (Invitrogen) and were used for
experiments 48–72 hr following transfection. In Figure 4G, the
FMRFamide receptor was expressed using a GFP-containing
IRES vector.
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Cells were fixed and stained as described [45]. Primary
antibodies used were rabbit anti-NPY (1:1000; T-4070; Peninsula
Laboratories), rabbit anti-FMRFamide (1:200; IHC8755; Penin-
sula Laboratories), guinea pig anti-insulin (1:5000; I8510; Sigma),
mouse anti-glucagon (1:2000; G2654; Sigma), rat anti-somatostat-
in (1:500; MAB354; Millipore), and rabbit anti-pancreatic
polypeptide (1:1000; AB939; Millipore). Secondary antibodies
were donkey anti-rabbit Alexa 488 (1:200; Invitrogen), donkey
anti-guinea pig; donkey anti-mouse; donkey anti-rat and donkey
anti-rabbit (conjugated to dylight 549; all used at 1:100; Jackson
ImmunoResearch). For double-staining experiments, antibodies
were applied sequentially. Control experiments showed there was
no significant bleed-through of the fluorescent labels or cross-
reactivity between antibodies. In some experiments the cells were
transfected with 0.65 mg pNPY-Venus [46]. Most images were
obtained with a Nikon TE2000U microscope with a 606 (1.4
numerical aperture) oil-immersion objective and a Retiga 1300
monochrome camera and Image-Pro software. Data in
Figure 1B,C were obtained using a Leica DM IRE2 confocal
microscope with a 636water immersion objective.
In situ immunohistochemistry
Pancreatic tissue was fixed in 4% paraformaldehyde in PBS
overnight at room temperature (RT) and stored at 4uC in PBS
containing 30% sucrose. Tissue was embedded in cryomatrix
medium and 20 mm frozen sections were prepared. Sections were
fixed for 20 min in 4% paraformaldehyde, permeabilized (0.3%
TritonX-100 in PBS for 15 min), maintained in blocking solution
(PBS containing 0.05% Triton X-100 and 0.25% BSA) for
30 mins, then incubated overnight at 4uC in primary antibody in
blocking solution. Slices were washed (six times for 10 min with
PBS) and incubated with a secondary antibody for 90 mins at RT.
After washing, the sections were mounted in Vectashield.
Reverse transcription-PCR
RNA was isolated from rat INS-1 cells growing on a single 35 mm
dish and RT-PCR was performed as described [45]. The forward
NPY primer was 59- GCTAGGTAACAAACGAATGGGG-39,a n d
the reverse NPY primer was 59-CACATGGAAGGGTCTT-
CAAGC-39 (288 bp product). The forward insulin primer was 59-
TGTGGTTCTCACTTGGTGGA-39, the reverse insulin primer
was 59-CAGTGCCAAGGTCTGAAGGT-39 (156 bp product).
The forward MafA primer was 59-TTCAGCAAGGAGGAGGT-
CAT-39, the reverse MafA primer was 59-CCGCCAACTTCTCG-
TATTTC-39 (217 bp product). All primers were intron spanning.
Single cell RT-PCR
Pancreatic cultures were prepared from P1 NPY-GFP mice and
singleGFP positive cellswereaspirated into 5–10 mm diameter patch
pipettes containing 1 ml DEPC-treated water. The subsequent steps
largely followed those of van den Pol et al [19]. Briefly, the pipette
contents were ejected into a PCR tube containing 2 ml5 6RT buffer,
0.5 mlR N a s i n( 4 0U / ml)and4.5 ml water. Reverse primer was added
(1 mlo f2 0mM stock) and the mixture heated to 70uCfo r5m i n st h e n
stored on ice. Reverse transcription reaction was performed by
incubation at 42uC for 60 mins after the addition of 1 mlo f2 0 0U / ml
Moloney murine leukemia virus reverse transcriptase and 1 mlo f
10 mM dNTPs. The reaction was terminated by incubation at 95uC
for 5 min. RNA in an RNA : DNA duplex was digested by the
addition of 0.5 mlo f2U / ml RNase H and incubation at 37uCf o r
20 mins. Hot start PCR used an intron spanning primer for the
mouse insulin2 prohormone (forward primer 59-TTTGTCAAG-
CAGCACCTTTG-39; reverse primer 59-GCTGGTAGAGGGAG-
CAGATG-39; 241 bp product). Each reaction contained 5 mlo f1 0 6
buffer, 2.5 mlo f2 0mMp r i m e rst o c k ,1mlo f5U/ mlTaqpolymerase,
5 ml of the reverse transcription reaction, and water to a final volume
of 50 ml. The PCR protocol was 94uC for 3 mins, then 94uCf o r4 5s ,
55uCf o r4 5s ,a n d7 2 uC for 60 s, for 35 cycles, and finally 72uCf o r
10 mins. Samples (20 ml) were analyzed on 2% agarose gels,
photographed and the image was inverted for clarity. Controls
included omission of reverse transcriptase (to reveal any genomic
contamination) and aspirated bath solution (to test for non-specific
amplification). Both controls were negative.
Acknowledgments
I thank Dr. Prabhu Ramamoorthy for participating in preliminary
experiments, Ms. Qian Wang for help with confocal microscopy, Dr.
Charles Nichols and the Department of Pharmacology (LSUHSC) for the
use of a confocal microscope and Dr. June Liu for critically reading the
manuscript.
Author Contributions
Conceived and designed the experiments: MDW. Performed the
experiments: MDW. Analyzed the data: MDW. Wrote the paper: MDW.
References
1. Hutton JC, Penn EJ, Peshavaria M (1983) Low-molecular-weight constituents of
isolated insulin-secretory granules. Bivalent cations, adenine nucleotides and
inorganic phosphate. Biochem J 210: 297–305.
2. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, et al. (1991) GABA and
pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and
GABA with synaptic-like microvesicles suggests their role in GABA storage and
secretion. Embo J 10: 1275–1284.
3. Cetin Y, Aunis D, Bader MF, Galindo E, Jorns A, et al. (1993) Chromostatin, a
chromogranin A-derived bioactive peptide, is present in human pancreatic
insulin (beta) cells. Proc Natl Acad Sci U S A 90: 2360–2364.
4. Myrsen-Axcrona U, Ekblad E, Sundler F (1997) Developmental expression of
NPY, PYY and PP in the rat pancreas and their coexistence with islet hormones.
Regul Pept 68: 165–175.
5. Jacques-Silva MC, Correa-Medina M, Cabrera O, Rodriguez-Diaz R,
Makeeva N, et al. ATP-gated P2X3 receptors constitute a positive autocrine
signal for insulin release in the human pancreatic beta cell. Proc Natl Acad
Sci U S A 107: 6465–6470.
6. Braun M, Wendt A, Buschard K, Salehi A, Sewing S, et al. (2004) GABAB
receptor activation inhibits exocytosis in rat pancreatic beta-cells by G-protein-
dependent activation of calcineurin. J Physiol 559: 397–409.
7. Bennet WM, Wang ZL, Jones PM, Wang RM, James RF, et al. (1996) Presence
of neuropeptide Y and its messenger ribonucleic acid in human islets: evidence
for a possible paracrine role. J Clin Endocrinol Metab 81: 2117–2120.
8. German I, Roper MG, Kalra SP, Rhinehart E, Kennedy RT (2001) Capillary
liquid chromatography of multiple peptides with on-line capillary electrophoresis
immunoassay detection. Electrophoresis 22: 3659–3667.
9. Moltz JH, McDonald JK (1985) Neuropeptide Y: direct and indirect action on
insulin secretion in the rat. Peptides 6: 1155–1159.
10. Imai Y, Patel HR, Hawkins EJ, Doliba NM, Matschinsky FM, et al. (2007)
Insulin secretion is increased in pancreatic islets of neuropeptide Y-deficient
mice. Endocrinology 148: 5716–5723.
11. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, et al. (1998) Obesity
and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice.
Proc Natl Acad Sci U S A 95: 15659–15664.
12. Jackerott M, Oster A, Larsson LI (1996) PYY in developing murine islet cells:
comparisons to development of islet hormones, NPY, and BrdU incorporation.
J Histochem Cytochem 44: 809–817.
13. Gu C, Stein GH, Pan N, Goebbels S, Hornberg H, et al. Pancreatic beta cells require
NeuroD to achieve and maintain functional maturity. Cell Metab 11: 298–310.
14. Teitelman G, Alpert S, Polak JM, Martinez A, Hanahan D (1993) Precursor
cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal
proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic
polypeptide. Development 118: 1031–1039.
15. Myrsen U, Sundler F (1995) Neuropeptide Y is expressed in islet somatostatin
cells of the hamster pancreas: a combined immunocytochemical and in situ
hybridization study. Regul Pept 57: 65–76.
NPY and Pancreatic ß Cells
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e1947816. Ponery AS, Adeghate E (2000) Distribution of NPY and SP and their effects on
glucagon secretion from the in vitro normal and diabetic pancreatic tissues.
Peptides 21: 1503–1509.
17. Michael DJ, Cai H, Xiong W, Ouyang J, Chow RH (2006) Mechanisms of
peptide hormone secretion. Trends Endocrinol Metab 17: 408–415.
18. MacDonald PE, Braun M, Galvanovskis J, Rorsman P (2006) Release of small
transmitters through kiss-and-run fusion pores in rat pancreatic beta cells. Cell
Metab 4: 283–290.
19. van den Pol AN, Yao Y, Fu LY, Foo K, Huang H, et al. (2009) Neuromedin B
and gastrin-releasing peptide excite arcuate nucleus neuropeptide Y neurons in a
novel transgenic mouse expressing strong Renilla green fluorescent protein in
NPY neurons. J Neurosci 29: 4622–4639.
20. Waeber G, Thompson N, Waeber B, Brunner HR, Nicod P, et al. (1993)
Neuropeptide Y expression and regulation in a differentiated rat insulin-
secreting cell line. Endocrinology 133: 1061–1067.
21. Arumugam R, Fleenor D, Freemark M (2007) Lactogenic and somatogenic
hormones regulate the expression of neuropeptide Y and cocaine- and
amphetamine-regulated transcript in rat insulinoma (INS-1) cells: interactions
with glucose and glucocorticoids. Endocrinology 148: 258–267.
22. Whim MD, Moss GW (2001) A novel technique that measures peptide secretion
on a millisecond timescale reveals rapid changes in release. Neuron 30: 37–50.
23. Whim MD (2006) Near simultaneous release of classical and peptide
cotransmitters from chromaffin cells. J Neurosci 26: 6637–6642.
24. Cottrell GA (1997) The first peptide-gated ion channel. J Exp Biol 200:
2377–2386.
25. Lingueglia E, Champigny G, Lazdunski M, Barbry P (1995) Cloning of the
amiloride-sensitive FMRFamide peptide-gated sodium channel. Nature 378:
730–733.
26. Chow RH, von Ruden L, Neher E (1992) Delay in vesicle fusion revealed by
electrochemical monitoring of single secretory events in adrenal chromaffin cells.
Nature 356: 60–63.
27. Smith PA, Proks P, Ashcroft FM (1999) Quantal analysis of 5-hydroxytrypta-
mine release from mouse pancreatic beta-cells. J Physiol 521 Pt 3: 651–664.
28. Ammala C, Ashcroft FM, Rorsman P (1993) Calcium-independent potentiation
of insulin release by cyclic AMP in single beta-cells. Nature 363: 356–358.
29. Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, et al. (2003)
Epac-selective cAMP analog 8-pCPT-29-O-Me-cAMP as a stimulus for Ca2+-
induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem 278:
8279–8285.
30. Seino S, Takahashi H, Fujimoto W, Shibasaki T (2009) Roles of cAMP
signalling in insulin granule exocytosis. Diabetes Obes Metab 11 Suppl 4:
180–188.
31. Kang G, Chepurny OG, Rindler MJ, Collis L, Chepurny Z, et al. (2005) A
cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release
in mouse pancreatic beta cells. J Physiol 566: 173–188.
32. Kang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, et al. (2006)
cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity
in human pancreatic beta cells and rat INS-1 cells. J Physiol 573: 595–609.
33. Myrsen U, Ahren B, Sundler F (1995) Neuropeptide Y is expressed in
subpopulations of insulin- and non-insulin-producing islet cells in the rat after
dexamethasone treatment: a combined immunocytochemical and in situ
hybridisation study. Regul Pept 60: 19–31.
34. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine
pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84–116.
35. Cabrera O, Jacques-Silva MC, Speier S, Yang SN, Kohler M, et al. (2008)
Glutamate is a positive autocrine signal for glucagon release. Cell Metab 7:
545–554.
36. Myrsen-Axcrona U, Karlsson S, Sundler F, Ahren B (1997) Dexamethasone
induces neuropeptide Y (NPY) expression and impairs insulin release in the
insulin-producing cell line RINm5F. Release of NPY and insulin through
different pathways. J Biol Chem 272: 10790–10796.
37. Marx R, El Meskini R, Johns DC, Mains RE (1999) Differences in the ways
sympathetic neurons and endocrine cells process, store, and secrete exogenous
neuropeptides and peptide-processing enzymes. J Neurosci 19: 8300–8311.
38. Morgan DG, Kulkarni RN, Hurley JD, Wang ZL, Wang RM, et al. (1998)
Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated
via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat
insulinoma cells. Diabetologia 41: 1482–1491.
39. Cho YR, Kim CW (2004) Neuropeptide Y promotes beta-cell replication via
extracellular signal-regulated kinase activation. Biochem Biophys Res Commun
314: 773–780.
40. Adeghate E, Ponery AS, Pallot DJ, Singh J (2001) Distribution of vasoactive
intestinal polypeptide, neuropeptide-Y and substance P and their effects on
insulin secretion from the in vitro pancreas of normal and diabetic rats. Peptides
22: 99–107.
41. Jamal H, Jones PM, Byrne J, Suda K, Ghatei MA, et al. (1991) Peptide contents
of neuropeptide Y, vasoactive intestinal polypeptide, and beta-calcitonin gene-
related peptide and their messenger ribonucleic acids after dexamethasone
treatment in the isolated rat islets of Langerhans. Endocrinology 129:
3372–3380.
42. Hole RL, Pian-Smith MC, Sharp GW (1988) Development of the biphasic
response to glucose in fetal and neonatal rat pancreas. Am J Physiol 254:
E167–174.
43. Meneghel-Rozzo T, Rozzo A, Poppi L, Rupnik M (2004) In vivo and in vitro
development of mouse pancreatic beta-cells in organotypic slices. Cell Tissue
Res 316: 295–303.
44. Erickson JC, Clegg KE, Palmiter RD (1996) Sensitivity to leptin and
susceptibility to seizures of mice lacking neuropeptide Y. Nature 381: 415–421.
45. Ramamoorthy P, Whim MD (2008) Trafficking and fusion of neuropeptide Y-
containing dense-core granules in astrocytes. J Neurosci 28: 13815–13827.
46. Mitchell GC, Wang Q, Ramamoorthy P, Whim MD (2008) A common single
nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y.
J Neurosci 28: 14428–14434.
NPY and Pancreatic ß Cells
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e19478